PLSE
Pulse Biosciences, Inc. [PLSE] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
PLSE Stock Summary
Top 10 Correlated Stocks
PLSE
In the News
PLSE Financial details
Company Rating
-
Market Cap
398.73M
Income
-42.69M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
61
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-11.9
Forward P/E
-
PEG
2.47
P/S
-52938.48
P/B
9.11
P/C
-
P/FCF
-13.87
Quick Ratio
9.28
Current Ratio
9.5
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.9
EPS next Y
-
EPS next Q
-
EPS this Y
-49.43%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
15.79%
-
-
-
-
SMA20
-1.86%
SMA50
-6.8%
SMA100
-8.82%
Inst Own
-
Inst Trans
-
ROA
-61%
ROE
-160%
ROC
-0.66%
Gross Margin
14444%
Oper. Margin
442067%
Profit Margin
443600%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
3.78-13.62
52W High
+4.23%
52W Low
+351.67%
RSI
42.1
Rel Volume
0.6
Avg Volume
175.44K
Volume
104.8K
Perf Week
-4.91%
Perf Month
-4.85%
Perf Quarter
-11.67%
Perf Half Y
-10.91%
-
-
-
-
Beta
1.691
-
-
Volatility
0.46%, 0.46%
Prev Close
-5.38%
Price
13.55
Change
-5.77%
Company Profile
- Volume Average 175.44K
- Market Capitalization 398.73M
- Employee 61
- CEO Mr. Kevin P. Danahy
- Headquarters Hayward,CA,US
- IPO Date 2016-05-18
-
Website
https://www.pulsebiosciences.com 
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
